Sanofiaventis announced today key results from three studies evaluating Eloxatin® (oxaliplatin injection) in various gastrointestinal tumor types (colorectal, pancreatic and gastric cancers). These results were presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, Georgia.
Sanofi-aventis announced today that a meta-analysis performed on seven clinical trials in patients with advanced non-small cell lung cancer showed that patients receiving Taxotere® (docetaxel) Injection Concentrate had demonstrated overall survival and less febrile neutropenia than those treated with vinca-alkaloid (vinorelbine or vindesine) regimens.
Sanofi-aventis befinner sig i en expansiv fas med förberedelser inför lansering av ny produkt och många spännande studier i pipeline. Detta resulterar i en omfattande rekrytering.
The Combined General Meeting of Shareholders of sanofi-aventis was held May 31, 2006.
- 430 abstracts from studies involving Taxotere® or Eloxatin® accepted at the meetings scientific sessions -
Lyon, France May 11, 2006 A study published online in The Lancet on May 11 demonstrated that multiple dosage formulations of a candidate H5N1 influenza vaccine developed by sanofi pasteur were well-tolerated and generated an immune response, with and without adjuvant. Of the formulations being tested, an alum-adjuvanted 30 microgram (µg) dosage generated the most substantive immune response (
Paris, France, May 9, 2006 - Sanofi-aventis announced today that PLAVIX® (clopidogrel) has been launched in Japan.
First quarter of 2006: Sales growth of 9.6% on a reported basis and 4.9% on a comparable basis1 52.8% growth in adjusted EPS1 and 19.8% excluding selected items3
Läkemedlet Acomplia (rimonabant) har idag fått så kallad positive opinion från den europeiska läkemedelsmyndigheten EMEA och förväntas därmed bli godkänt i Sverige och övriga Europa. Formellt beslut tas av EU-kommissionen senare i sommar. Sanofi-aventis räknar med att Acomplia kommer att finnas tillgänglig på den svenska marknaden i slutet av det här året.
The 1st quarter 2006 sales & earnings will be released at 7.00 am (Paris time) and will be available online at http://www.sanofi-aventis.com.
As part of its strategy to strengthen its presence in Japan, sanofi-aventis announced today that it has agreed with Astellas Pharma Inc. to accelerate the transfer of all rights to rimonabant in Japan from a joint-venture company held by the two groups to sanofi-aventis.
Achieving good glycemic control with less hypoglycemia and less weight gain
TAXOTERE® RECEIVES POSITIVE OPINION FROM THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE RECOMMENDING APPROVAL IN THE EUROPEAN UNION FOR METASTATIC STOMACH CANCER
TAXOTERE®-based regimen demonstrates a 23% reduction in the risk of mortality in patients with advanced stomach cancer
Brigham and Womens Cardiac Group Finds Enoxaparin Strategy is Better Than Commonly Administered Blood Thinning Strategy For Heart Attacks - New therapy significantly reduces risk of repeat heart attack and death
Shikimic acid is a key raw material for the manufacture of Tamiflu®s active ingredient
Results from the IDEA Study Highlight the Rising Worldwide Pandemic of Abdominal Obesity
Om svensken själv får välja är det den tjocka magen som ska bort. 51 procent av svenskarna vill ha smalare midja. En majoritet anger omsorg om hälsan som skäl, inte utseende. Det visar en färsk undersökning från Temo.
NV1FGF Injection Reduces and Delays Risks of Amputation in Patients with Limb Ischemia
Results from the CHARISMA trial showed that the combination of the antiplatelet agents clopidogrel and aspirin did not demonstrate a statistically significant reduction in the risk of heart attack, stroke or cardiovascular death compared to placebo and aspirin in a broad population of patients with either established atherothrombotic disease or multiple risk factors for atherothrombotic events.